BRPI1014876A2 - "diamidas de azetidinila como inibidores de monoacilglicerol lipase." - Google Patents

"diamidas de azetidinila como inibidores de monoacilglicerol lipase."

Info

Publication number: BRPI1014876A2
Authority: BR; Brazil
Prior art keywords: lipase inhibitors; monoacylglycerol lipase; diamides; azetidinyl; azetidinyl diamides
Prior art date: 2009-04-22

Application number

BRPI1014876A

Other languages

English (en)

Inventor

Bin Zhu

Christopher M Flores

Haiyan Bian

John Mabus

Jose Clemente

Kristen M Chevalier

Li Liu

Mark E Mcdonnell

Mark J Macielag

Peter J Connolly

Philip M Pitis

Shu-Chen Lin

Sui-Po Zhang

Yue-Mei

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-22

Filing date

2010-04-22

Publication date

2016-04-12

2010-04-22 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2016-04-12 Publication of BRPI1014876A2 publication Critical patent/BRPI1014876A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Otolaryngology (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Anesthesiology (AREA)
Communicable Diseases (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Diabetes (AREA)
Toxicology (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

BRPI1014876A 2009-04-22 2010-04-22 "diamidas de azetidinila como inibidores de monoacilglicerol lipase." BRPI1014876A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US17164909P	2009-04-22	2009-04-22
US17165809P	2009-04-22	2009-04-22
PCT/US2010/032089 WO2010124114A1 (en)	2009-04-22	2010-04-22	Azetidinyl diamides as monoacylglycerol lipase inhibitors

Publications (1)

Publication Number	Publication Date
BRPI1014876A2 true BRPI1014876A2 (pt)	2016-04-12

Family

ID=42208680

Family Applications (8)

Application Number	Title	Priority Date	Filing Date
BRPI1013545A BRPI1013545A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores de monoacilglicerol lipase
BRPI1013540-5A BRPI1013540A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores de monoacilglicerol lipases
BRPI1013538A BRPI1013538A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores de monoacilglicerol lipase
BRPI1015238A BRPI1015238A2 (pt)	2009-04-22	2010-04-22	diamidas de azetidilina como inibidores de monoaciglicerol lipase
BRPI1014281A BRPI1014281A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores da monoacilglicerol lipase
BRPI1014284A BRPI1014284A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores da monoacilglicerol lipase
BRPI1014885A BRPI1014885A8 (pt)	2009-04-22	2010-04-22	"azetidinil diamidas como inibidores de monoacilglicerol lipase."
BRPI1014876A BRPI1014876A2 (pt)	2009-04-22	2010-04-22	"diamidas de azetidinila como inibidores de monoacilglicerol lipase."

Family Applications Before (7)

Application Number	Title	Priority Date	Filing Date
BRPI1013545A BRPI1013545A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores de monoacilglicerol lipase
BRPI1013540-5A BRPI1013540A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores de monoacilglicerol lipases
BRPI1013538A BRPI1013538A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores de monoacilglicerol lipase
BRPI1015238A BRPI1015238A2 (pt)	2009-04-22	2010-04-22	diamidas de azetidilina como inibidores de monoaciglicerol lipase
BRPI1014281A BRPI1014281A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores da monoacilglicerol lipase
BRPI1014284A BRPI1014284A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores da monoacilglicerol lipase
BRPI1014885A BRPI1014885A8 (pt)	2009-04-22	2010-04-22	"azetidinil diamidas como inibidores de monoacilglicerol lipase."

Country Status (22)

Country	Link
US (16)	US8450303B2 (pt)
EP (8)	EP2421851A1 (pt)
JP (8)	JP5649644B2 (pt)
KR (8)	KR20120035146A (pt)
CN (8)	CN102459255A (pt)
AR (8)	AR076378A1 (pt)
AU (9)	AU2010238740A1 (pt)
BR (8)	BRPI1013545A2 (pt)
CA (8)	CA2759604A1 (pt)
DK (1)	DK2421825T3 (pt)
ES (2)	ES2455744T3 (pt)
HK (2)	HK1170221A1 (pt)
HR (1)	HRP20140295T1 (pt)
IL (8)	IL215781A0 (pt)
PL (1)	PL2421825T3 (pt)
PT (1)	PT2421825E (pt)
RS (1)	RS53235B (pt)
RU (8)	RU2011147181A (pt)
SI (1)	SI2421825T1 (pt)
SM (1)	SMT201400034B (pt)
TW (8)	TWI465446B (pt)
WO (8)	WO2010124112A1 (pt)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010011493A1 (en)	2008-07-21	2010-01-28	Novartis Ag	Silicone-containing polymeric materals with hydrolyzable groups
WO2010124112A1 (en) *	2009-04-22	2010-10-28	Janssen Pharmaceutica Nv	Azetidinyl diamides as monoacylglycerol lipase inhibitors
US9082128B2 (en) *	2009-10-19	2015-07-14	Uniloc Luxembourg S.A.	System and method for tracking and scoring user activities
US9051296B2 (en)	2009-11-16	2015-06-09	Raqualia Pharma Inc.	Aryl carboxamide derivatives as TTX-S blockers
WO2011112263A1 (en)	2010-03-11	2011-09-15	New York University	AMIDO COMPOUNDS AS RORγt MODULATORS AND USES THEREOF
RU2013114771A (ru)	2010-09-03	2014-10-10	Янссен Фармацевтика Нв	Диамиды азетидинила как ингибиторы моноацилглицерол липазы
CN103080103A (zh)	2010-09-27	2013-05-01	詹森药业有限公司	作为单酰甘油脂肪酶抑制剂的氧代哌嗪-氮杂环丁烷酰胺和氧代二氮杂*-氮杂环丁烷酰胺
CN102417483A (zh) *	2010-09-27	2012-04-18	中国药科大学	作为parp抑制剂的2-苯基-1h-苯并咪唑-4-甲酸酯衍生物
CN103261189B (zh)	2010-10-22	2015-01-28	詹森药业有限公司	作为单酰基甘油脂肪酶抑制剂的氨基-吡咯烷-氮杂环丁烷二酰胺
US8513423B2 (en)	2010-10-22	2013-08-20	Janssen Pharmaceutica, Nv	Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
KR20130142137A (ko) *	2010-10-22	2013-12-27	얀센 파마슈티카 엔.브이.	모노아실글리세롤 리파아제 억제제로서의 피페리딘-4-일-아제티딘 다이아미드
KR20140009291A (ko)	2011-01-20	2014-01-22	머크 샤프 앤드 돔 코포레이션	미네랄로코르티코이드 수용체 길항제
US9388164B2 (en)	2011-05-03	2016-07-12	Agios Pharmaceuticals, Inc	Methods of using pyruvate kinase activators
US8835417B2 (en)	2011-09-30	2014-09-16	Janssen Pharmaceutica Nv	Crystalline hydrochloride salt of (1-(4-fluorophenyl)-1H-indol-5-yl)-(3-(4-(thiazole-2-carbonyl)piperazin-1-yl)azetidin-1-yl)methanone
MX2014003883A (es) *	2011-09-30	2014-08-27	Janssen Pharmaceutica Nv	Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados.
KR20140068243A (ko) *	2011-09-30	2014-06-05	얀센 파마슈티카 엔.브이.	대사 질환 및 관련 장애의 치료를 위한 모노아실글리세롤 리파제 억제제
AU2013207252B2 (en)	2012-01-06	2016-06-09	H.Lundbeck A/S	Carbamate compounds and pharmaceutical compositions thereof
CN102603485A (zh) *	2012-02-07	2012-07-25	北京颖新泰康国际贸易有限公司	制备2-甲基-3-苯基苯甲醇的方法
TWI562295B (en)	2012-07-31	2016-12-11	Mediatek Inc	Semiconductor package and method for fabricating base for semiconductor package
NZ707778A (en)	2012-11-08	2019-03-29	Agios Pharmaceuticals Inc	Therapeutic compounds and compositions and their use as pkm2 modulators
EP3401314B1 (en) *	2013-03-15	2023-11-08	Araxes Pharma LLC	Covalent inhibitors of kras g12c
WO2014139144A1 (en)	2013-03-15	2014-09-18	Agios Pharmaceuticals, Inc.	Therapeutic compounds and compositions
WO2014143659A1 (en)	2013-03-15	2014-09-18	Araxes Pharma Llc	Irreversible covalent inhibitors of the gtpase k-ras g12c
UY35464A (es)	2013-03-15	2014-10-31	Araxes Pharma Llc	Inhibidores covalentes de kras g12c.
JP6370887B2 (ja)	2013-05-23	2018-08-08	バイエル・ファルマ・アクティエンゲゼルシャフト	オンデマンド避妊のための医薬組成物およびその使用、ならびにこの医薬組成物の適用体制
TWI659021B (zh)	2013-10-10	2019-05-11	亞瑞克西斯製藥公司	Ｋｒａｓｇ１２ｃ之抑制劑
KR101861937B1 (ko) *	2013-11-12	2018-05-28	에프. 호프만-라 로슈 아게	신경변성 장애의 치료를 위한 신경성 제제로서의 피라진-2-카복스아마이드
EP3087067B1 (en) *	2013-12-26	2018-10-24	Takeda Pharmaceutical Company Limited	4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
JO3556B1 (ar)	2014-09-18	2020-07-05	Araxes Pharma Llc	علاجات مدمجة لمعالجة السرطان
EP3197450A1 (en) *	2014-09-22	2017-08-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of fibrosis
WO2016049568A1 (en)	2014-09-25	2016-03-31	Araxes Pharma Llc	Methods and compositions for inhibition of ras
US9862701B2 (en)	2014-09-25	2018-01-09	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
EP3279191B1 (en) *	2015-03-30	2020-09-02	Takeda Pharmaceutical Company Limited	Heterocyclic compound
US10246424B2 (en)	2015-04-10	2019-04-02	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use thereof
EP3283462B1 (en)	2015-04-15	2020-12-02	Araxes Pharma LLC	Fused-tricyclic inhibitors of kras and methods of use thereof
TN2018000020A1 (en) *	2015-07-20	2019-07-08	Genzyme Corp	Colony stimulating factor-1 receptor (csf-1r) inhibitors.
US10144724B2 (en)	2015-07-22	2018-12-04	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use thereof
ES2823049T3 (es)	2015-07-31	2021-05-05	Pfizer	Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-ilo y derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ilo como inhibidores de MAGL
WO2017058915A1 (en)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
EP3356354A1 (en)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
US10689356B2 (en)	2015-09-28	2020-06-23	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
WO2017058728A1 (en)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
EP3356351A1 (en)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
US10882847B2 (en) *	2015-09-28	2021-01-05	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en)	2015-09-28	2020-12-29	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
JP2018533939A (ja)	2015-10-19	2018-11-22	アラクセスファーマエルエルシー	Ｒａｓの阻害剤をスクリーニングするための方法
KR20240113606A (ko)	2015-11-16	2024-07-22	아락세스 파마 엘엘씨	치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
WO2017100546A1 (en)	2015-12-09	2017-06-15	Araxes Pharma Llc	Methods for preparation of quinazoline derivatives
WO2017129801A1 (en)	2016-01-27	2017-08-03	Universität Zürich	Use of gabaa receptor modulators for treatment of itch
WO2017143283A1 (en)	2016-02-19	2017-08-24	Abide Therapeutics, Inc.	Radiolabeled monoacylglycerol lipase occupancy probe
WO2017172979A1 (en)	2016-03-30	2017-10-05	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use
ES2804580T3 (es)	2016-03-31	2021-02-08	Takeda Pharmaceuticals Co	Compuesto heterocíclico
US10610520B2 (en)	2016-03-31	2020-04-07	Takeda Pharmaceutical Company Limited	Heterocyclic compound
US10646488B2 (en)	2016-07-13	2020-05-12	Araxes Pharma Llc	Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
JP2019529484A (ja)	2016-09-29	2019-10-17	アラクセスファーマエルエルシー	Ｋｒａｓｇ１２ｃ変異体タンパク質の阻害剤
US10377743B2 (en)	2016-10-07	2019-08-13	Araxes Pharma Llc	Inhibitors of RAS and methods of use thereof
JOP20190106A1 (ar) *	2016-11-16	2019-05-09	Lundbeck La Jolla Research Center Inc	مثبطات أحادي أسيل جليسرول ليباز (magl)
CN110382479A (zh)	2017-01-20	2019-10-25	辉瑞大药厂	作为magl抑制剂的氨基甲酸1,1,1-三氟-3-羟基丙-2-基酯衍生物
RU2726631C1 (ru)	2017-01-23	2020-07-15	Пфайзер Инк.	Гетероциклические спиросоединения в качестве ингибиторов magl
EP3573970A1 (en)	2017-01-26	2019-12-04	Araxes Pharma LLC	1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
US11358959B2 (en)	2017-01-26	2022-06-14	Araxes Pharma Llc	Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018140513A1 (en)	2017-01-26	2018-08-02	Araxes Pharma Llc	1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US11059819B2 (en)	2017-01-26	2021-07-13	Janssen Biotech, Inc.	Fused hetero-hetero bicyclic compounds and methods of use thereof
EP3573954A1 (en)	2017-01-26	2019-12-04	Araxes Pharma LLC	Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
HRP20230233T1 (hr)	2017-05-23	2023-04-14	H. Lundbeck A/S	Inhibitori pirazola magl
SG10202113146UA (en)	2017-05-25	2021-12-30	Araxes Pharma Llc	Covalent inhibitors of kras
EP3630747A1 (en)	2017-05-25	2020-04-08	Araxes Pharma LLC	Quinazoline derivatives as modulators of mutant kras, hras or nras
WO2018218071A1 (en)	2017-05-25	2018-11-29	Araxes Pharma Llc	Compounds and methods of use thereof for treatment of cancer
MX2020007318A (es)	2017-09-29	2020-08-24	Takeda Pharmaceuticals Co	Compuesto heterociclico.
AU2019234670B2 (en)	2018-03-13	2023-11-23	Takeda Pharmaceutical Company Limited	Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
US11932633B2 (en)	2018-05-07	2024-03-19	Mirati Therapeutics, Inc.	KRas G12C inhibitors
KR20210010475A (ko)	2018-05-15	2021-01-27	룬드벡 라 졸라 리서치 센터 인코포레이티드	Magl 저해제
AU2019312670A1 (en)	2018-08-01	2021-02-04	Araxes Pharma Llc	Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
CN109020890B (zh) *	2018-09-12	2022-02-08	南京大学	一类饱和脂肪环骈吡唑衍生物的制备及其应用
CA3118752A1 (en) *	2018-11-09	2020-05-14	Vivace Therapeutics, Inc.	Bicyclic compounds
SG11202105320YA (en) *	2018-11-28	2021-06-29	H Lundbeck As	Methods of treating disease with magl inhibitors
WO2020146613A1 (en)	2019-01-10	2020-07-16	Mirati Therapeutics, Inc.	Kras g12c inhibitors
US20220073494A1 (en) *	2019-01-31	2022-03-10	Kyorin Pharmaceutical Co., Ltd.	15-pgdh inhibitors
JP7413346B2 (ja)	2019-03-06	2024-01-15	第一三共株式会社	ピロロピラゾール誘導体
SG11202111404XA (en)	2019-04-16	2021-11-29	Vivace Therapeutics Inc	Bicyclic compounds
CN114615981B (zh)	2019-08-29	2024-04-12	米拉蒂治疗股份有限公司	Kras g12d抑制剂
WO2021055589A1 (en)	2019-09-18	2021-03-25	Shire Human Genetic Therapies, Inc.	Heteroaryl plasma kallikrein inhibitors
PT4031547T (pt)	2019-09-18	2024-08-27	Takeda Pharmaceuticals Co	Inibidores de calicreína plasmática e utilizações dos mesmos
MX2022003537A (es)	2019-09-24	2022-07-11	Mirati Therapeutics Inc	Terapias de combinacion.
IL294048A (en)	2019-12-20	2022-08-01	Mirati Therapeutics Inc	sos1 inhibitors
CN115335043A (zh) *	2020-01-23	2022-11-11	迈欧伏特治疗公司	Pgdh抑制剂以及制备和使用方法
EP3875452A1 (en) *	2020-03-04	2021-09-08	Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis	Monoacylglycerol lipase inhibitors
EP4126825A1 (en) *	2020-03-26	2023-02-08	Janssen Pharmaceutica NV	Aminocyclobutanes as monoacylglycerol lipase modulators
JP2024500919A (ja)	2020-12-23	2024-01-10	ジェンザイム・コーポレーション	重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤
KR102682408B1 (ko) *	2021-05-12	2024-07-05	에이치케이이노엔 주식회사	신규한 벤조티아졸 유도체, 이의 제조방법 및 이의 간질환 예방 또는 치료 용도
WO2023009618A1 (en) *	2021-07-28	2023-02-02	Epirium Bio, Inc.	Bicyclic pgdh inhibitors and methods of making and using

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9600235D0 (en) *	1996-01-05	1996-03-06	Pfizer Ltd	Therapeutic agents
WO1998037077A1 (en)	1997-02-24	1998-08-27	Zymogenetics, Inc.	Calcitonin mimetics
WO1999019297A1 (en)	1997-10-15	1999-04-22	Coelacanth Chemical Corporation	Synthesis of azetidine derivatives
WO2000063168A1 (en)	1999-04-16	2000-10-26	Coelacanth Chemical Corporation	Synthesis of azetidine derivatives
US6566356B2 (en)	2000-03-03	2003-05-20	Aventis Pharma S.A.	Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
AR033517A1 (es)	2000-04-08	2003-12-26	Astrazeneca Ab	Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
FR2829028B1 (fr)	2001-08-29	2004-12-17	Aventis Pharma Sa	Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
AR037364A1 (es) *	2001-11-16	2004-11-03	Schering Corp	Azetidinil diaminas utiles como ligandos del receptor de nociceptina orl-1
US6995144B2 (en) *	2002-03-14	2006-02-07	Eisai Co., Ltd.	Nitrogen containing heterocyclic compounds and medicines containing the same
WO2004002531A1 (ja) *	2002-06-26	2004-01-08	Ono Pharmaceutical Co., Ltd.	血管の収縮または拡張による疾患治療剤
DE60312042T2 (de)	2002-12-23	2007-10-31	Janssen Pharmaceutica N.V.	Substituierte 1-piperidin-4-yl-4-azetidin-3-yl-piperazinderivate und deren verwendung als neurokininantagonisten
FR2854633B1 (fr) *	2003-05-07	2005-06-24	Sanofi Synthelabo	Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
WO2004110451A1 (en) *	2003-06-10	2004-12-23	Janssen Pharmaceutica N.V.	Combinations for opioid-based treatment of pain comprising 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives
EP1702916A1 (en)	2005-03-18	2006-09-20	Santhera Pharmaceuticals (Schweiz) GmbH	DPP-IV inhibitors
MX2007015606A (es) *	2005-06-23	2008-02-25	Astrazeneca Ab	Nuevos derivados de azetidina como antagonistas del receptor de neuroquinina para el tratamiento de enfermedades gastrointestinales.
AU2006331850A1 (en)	2005-12-21	2007-07-05	Schering Corporation	Substituted aniline derivatives useful as histamine H3 antagonists
DE102006016023A1 (de) *	2006-04-05	2007-10-11	Basf Ag	Funktionale Expression von Triacylglycerol-Lipasen
US8119676B2 (en)	2006-08-26	2012-02-21	Abbott GmbH & Co. HG	Substituted benzimidazolone derivatives, medicaments comprising them and their use
FR2915199B1 (fr) *	2007-04-18	2010-01-22	Sanofi Aventis	Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
FR2915198B1 (fr)	2007-04-18	2009-12-18	Sanofi Aventis	Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
FR2915197B1 (fr) *	2007-04-18	2009-06-12	Sanofi Aventis Sa	Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
WO2009117444A1 (en)	2008-03-17	2009-09-24	Northeastern University	Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
JP5715945B2 (ja)	2008-04-25	2015-05-13	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎＰｈａｒｍａｃｅｕｔｉｃａＮａａｍｌｏｚｅＶｅｎｎｏｏｔｓｃｈａｐ	モノアシルグリセロールリパーゼ（ｍｇｌｌ）の結晶構造
EP2180048B1 (en)	2008-10-09	2014-12-17	Janssen Pharmaceutica N.V.	Alternative crystal form of monoacylglycerol lipase (MGLL)
US8435977B2 (en)	2009-04-22	2013-05-07	Janssen Pharmaceutica, Nv	Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
ES2486674T3 (es)	2009-04-22	2014-08-19	Janssen Pharmaceutica N.V.	Piperazinilazetidinilamidas heteroaromáticas y aromáticas como inhibidores de la monoacilglicerol lipasa
WO2010124112A1 (en)	2009-04-22	2010-10-28	Janssen Pharmaceutica Nv	Azetidinyl diamides as monoacylglycerol lipase inhibitors
DE102012109699A1 (de) *	2012-10-11	2014-04-17	Pavel Abdulkin	Verfahren zum Bereitstellen einer Gold-Nano-Hülle um kleine, magnetische Partikel im Submikrometerbereich und so erhaltene Partikel

2010
- 2010-04-22 WO PCT/US2010/032086 patent/WO2010124112A1/en active Application Filing
- 2010-04-22 AU AU2010238740A patent/AU2010238740A1/en not_active Abandoned
- 2010-04-22 JP JP2012507378A patent/JP5649644B2/ja not_active Expired - Fee Related
- 2010-04-22 CN CN2010800287586A patent/CN102459255A/zh active Pending
- 2010-04-22 RU RU2011147181/04A patent/RU2011147181A/ru not_active Application Discontinuation
- 2010-04-22 AR ARP100101339A patent/AR076378A1/es unknown
- 2010-04-22 BR BRPI1013545A patent/BRPI1013545A2/pt not_active IP Right Cessation
- 2010-04-22 ES ES10716205.9T patent/ES2455744T3/es active Active
- 2010-04-22 AR ARP100101341A patent/AR076380A1/es not_active Application Discontinuation
- 2010-04-22 AU AU2010238738A patent/AU2010238738A1/en not_active Abandoned
- 2010-04-22 CN CN2010800287590A patent/CN102459228A/zh active Pending
- 2010-04-22 EP EP10716203A patent/EP2421851A1/en not_active Withdrawn
- 2010-04-22 EP EP10715461A patent/EP2421848A1/en not_active Withdrawn
- 2010-04-22 KR KR1020117027340A patent/KR20120035146A/ko not_active Application Discontinuation
- 2010-04-22 CA CA2759604A patent/CA2759604A1/en not_active Abandoned
- 2010-04-22 AR ARP100101343A patent/AR076382A1/es not_active Application Discontinuation
- 2010-04-22 CN CN2010800288396A patent/CN102459240A/zh active Pending
- 2010-04-22 CA CA2759614A patent/CA2759614C/en not_active Expired - Fee Related
- 2010-04-22 BR BRPI1013540-5A patent/BRPI1013540A2/pt not_active IP Right Cessation
- 2010-04-22 RU RU2011147230/04A patent/RU2011147230A/ru not_active Application Discontinuation
- 2010-04-22 CA CA2759501A patent/CA2759501A1/en not_active Abandoned
- 2010-04-22 EP EP10715457.7A patent/EP2421823B1/en active Active
- 2010-04-22 CA CA2759697A patent/CA2759697A1/en not_active Abandoned
- 2010-04-22 TW TW099112749A patent/TWI465446B/zh not_active IP Right Cessation
- 2010-04-22 PT PT107162059T patent/PT2421825E/pt unknown
- 2010-04-22 ES ES10715457.7T patent/ES2538326T3/es active Active
- 2010-04-22 KR KR1020117027313A patent/KR20120034615A/ko not_active Application Discontinuation
- 2010-04-22 US US12/765,179 patent/US8450303B2/en active Active
- 2010-04-22 CN CN2010800287463A patent/CN102803210A/zh active Pending
- 2010-04-22 US US12/765,048 patent/US8445477B2/en active Active
- 2010-04-22 RS RS20140136A patent/RS53235B/en unknown
- 2010-04-22 RU RU2011147233/04A patent/RU2549547C2/ru not_active IP Right Cessation
- 2010-04-22 AU AU2010239204A patent/AU2010239204A1/en not_active Abandoned
- 2010-04-22 WO PCT/US2010/032089 patent/WO2010124114A1/en active Application Filing
- 2010-04-22 US US12/765,018 patent/US8426401B2/en active Active
- 2010-04-22 EP EP10716672A patent/EP2421856A1/en not_active Withdrawn
- 2010-04-22 US US12/765,076 patent/US8367653B2/en active Active
- 2010-04-22 CN CN2010800287603A patent/CN102548982A/zh active Pending
- 2010-04-22 AR ARP100101337A patent/AR076376A1/es unknown
- 2010-04-22 KR KR1020117027341A patent/KR20110137831A/ko not_active Application Discontinuation
- 2010-04-22 TW TW099112750A patent/TW201103931A/zh unknown
- 2010-04-22 JP JP2012507389A patent/JP2012524805A/ja not_active Withdrawn
- 2010-04-22 US US12/765,487 patent/US8362001B2/en active Active
- 2010-04-22 TW TW099112752A patent/TW201105665A/zh unknown
- 2010-04-22 CA CA2759621A patent/CA2759621C/en not_active Expired - Fee Related
- 2010-04-22 BR BRPI1013538A patent/BRPI1013538A2/pt not_active IP Right Cessation
- 2010-04-22 TW TW099112747A patent/TWI483940B/zh not_active IP Right Cessation
- 2010-04-22 RU RU2011147236/04A patent/RU2011147236A/ru not_active Application Discontinuation
- 2010-04-22 KR KR1020117027691A patent/KR101705049B1/ko active IP Right Grant
- 2010-04-22 KR KR1020117027334A patent/KR20120034617A/ko not_active Application Discontinuation
- 2010-04-22 EP EP10715460A patent/EP2421824A1/en not_active Withdrawn
- 2010-04-22 US US12/765,103 patent/US8455476B2/en active Active
- 2010-04-22 RU RU2011147200/04A patent/RU2011147200A/ru not_active Application Discontinuation
- 2010-04-22 PL PL10716205T patent/PL2421825T3/pl unknown
- 2010-04-22 AR ARP100101342A patent/AR076381A1/es not_active Application Discontinuation
- 2010-04-22 EP EP10715456A patent/EP2421860A1/en not_active Withdrawn
- 2010-04-22 CA CA2759713A patent/CA2759713A1/en not_active Abandoned
- 2010-04-22 JP JP2012507390A patent/JP2012524806A/ja not_active Withdrawn
- 2010-04-22 KR KR1020117027713A patent/KR20120034623A/ko not_active Application Discontinuation
- 2010-04-22 US US12/765,254 patent/US8399454B2/en active Active
- 2010-04-22 JP JP2012507387A patent/JP5733840B2/ja not_active Expired - Fee Related
- 2010-04-22 CN CN201080028726.6A patent/CN102459166B/zh not_active Expired - Fee Related
- 2010-04-22 BR BRPI1015238A patent/BRPI1015238A2/pt not_active IP Right Cessation
- 2010-04-22 KR KR1020117027324A patent/KR20120034616A/ko not_active Application Discontinuation
- 2010-04-22 WO PCT/US2010/032092 patent/WO2010124116A1/en active Application Filing
- 2010-04-22 KR KR1020117027654A patent/KR101705697B1/ko active IP Right Grant
- 2010-04-22 RU RU2011147207/04A patent/RU2011147207A/ru not_active Application Discontinuation
- 2010-04-22 JP JP2012507377A patent/JP2012524800A/ja not_active Withdrawn
- 2010-04-22 TW TW099112748A patent/TW201105655A/zh unknown
- 2010-04-22 WO PCT/US2010/032049 patent/WO2010124086A1/en active Application Filing
- 2010-04-22 CA CA2759505A patent/CA2759505A1/en not_active Abandoned
- 2010-04-22 AR ARP100101338A patent/AR076377A1/es not_active Application Discontinuation
- 2010-04-22 JP JP2012507388A patent/JP2012524804A/ja not_active Withdrawn
- 2010-04-22 WO PCT/US2010/032045 patent/WO2010124082A1/en active Application Filing
- 2010-04-22 TW TW099112751A patent/TW201116280A/zh unknown
- 2010-04-22 AU AU2010239184A patent/AU2010239184A1/en not_active Abandoned
- 2010-04-22 JP JP2012507382A patent/JP2012524802A/ja not_active Withdrawn
- 2010-04-22 AU AU2010238732A patent/AU2010238732B2/en not_active Ceased
- 2010-04-22 EP EP10716205.9A patent/EP2421825B9/en active Active
- 2010-04-22 BR BRPI1014281A patent/BRPI1014281A2/pt not_active IP Right Cessation
- 2010-04-22 AR ARP100101340A patent/AR076379A1/es not_active Application Discontinuation
- 2010-04-22 AU AU2010238743A patent/AU2010238743A1/en not_active Abandoned
- 2010-04-22 BR BRPI1014284A patent/BRPI1014284A2/pt not_active IP Right Cessation
- 2010-04-22 DK DK10716205.9T patent/DK2421825T3/da active
- 2010-04-22 CA CA2759547A patent/CA2759547A1/en not_active Abandoned
- 2010-04-22 US US12/765,420 patent/US8362000B2/en active Active
- 2010-04-22 TW TW099112746A patent/TW201105654A/zh unknown
- 2010-04-22 CN CN201080028749.7A patent/CN102459167B/zh not_active Expired - Fee Related
- 2010-04-22 AR ARP100101335A patent/AR076374A1/es not_active Application Discontinuation
- 2010-04-22 CN CN2010800287478A patent/CN102459230A/zh active Pending
- 2010-04-22 EP EP10717365A patent/EP2421847A1/en not_active Withdrawn
- 2010-04-22 BR BRPI1014885A patent/BRPI1014885A8/pt not_active Application Discontinuation
- 2010-04-22 AU AU2010238736A patent/AU2010238736A1/en not_active Abandoned
- 2010-04-22 AU AU2010239188A patent/AU2010239188B2/en not_active Ceased
- 2010-04-22 BR BRPI1014876A patent/BRPI1014876A2/pt not_active IP Right Cessation
- 2010-04-22 SI SI201030535T patent/SI2421825T1/sl unknown
- 2010-04-22 WO PCT/US2010/032068 patent/WO2010124102A1/en active Application Filing
- 2010-04-22 RU RU2011147185/04A patent/RU2011147185A/ru not_active Application Discontinuation
- 2010-04-22 WO PCT/US2010/032082 patent/WO2010124108A1/en active Application Filing
- 2010-04-22 JP JP2012507392A patent/JP2012524807A/ja not_active Withdrawn
- 2010-04-22 TW TW099112753A patent/TW201103932A/zh unknown
- 2010-04-22 WO PCT/US2010/032095 patent/WO2010124119A1/en active Application Filing
- 2010-04-22 RU RU2011147206/04A patent/RU2569298C2/ru not_active IP Right Cessation
2011
- 2011-10-23 IL IL215781A patent/IL215781A0/en unknown
- 2011-10-23 IL IL215787A patent/IL215787A0/en unknown
- 2011-10-23 IL IL215773A patent/IL215773A/en not_active IP Right Cessation
- 2011-10-23 IL IL215798A patent/IL215798A0/en unknown
- 2011-10-23 IL IL215786A patent/IL215786A0/en unknown
- 2011-10-23 IL IL215780A patent/IL215780A/en not_active IP Right Cessation
- 2011-10-23 IL IL215785A patent/IL215785A0/en unknown
- 2011-10-23 IL IL215775A patent/IL215775A0/en unknown
2012
- 2012-10-29 HK HK12110778.3A patent/HK1170221A1/xx not_active IP Right Cessation
- 2012-10-30 HK HK12110891.5A patent/HK1170228A1/xx not_active IP Right Cessation
- 2012-12-17 US US13/716,705 patent/US8604017B2/en active Active
- 2012-12-18 US US13/718,056 patent/US8741887B2/en active Active
- 2012-12-18 US US13/718,257 patent/US8623858B2/en active Active
2013
- 2013-01-25 US US13/749,846 patent/US8722658B2/en active Active
- 2013-03-18 US US13/845,982 patent/US8697683B2/en active Active
- 2013-04-22 US US13/867,372 patent/US8962607B2/en active Active
- 2013-04-29 US US13/872,427 patent/US8697684B2/en active Active
- 2013-05-01 US US13/874,835 patent/US8691805B2/en active Active
2014
- 2014-03-20 SM SM201400034T patent/SMT201400034B/xx unknown
- 2014-03-27 HR HRP20140295AT patent/HRP20140295T1/hr unknown
2016
- 2016-03-03 AU AU2016201405A patent/AU2016201405A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2759604A1 (en)	2010-10-28
TW201105655A (en)	2011-02-16
TW201105654A (en)	2011-02-16
JP5733840B2 (ja)	2015-06-10
RU2011147185A (ru)	2013-05-27
EP2421825B9 (en)	2014-08-20
CN102548982A (zh)	2012-07-04
US20100331299A1 (en)	2010-12-30
RU2549547C2 (ru)	2015-04-27
WO2010124086A1 (en)	2010-10-28
AU2016201405A1 (en)	2016-03-24
SI2421825T1 (sl)	2014-04-30
BRPI1014885A2 (pt)	2016-04-19
TW201103931A (en)	2011-02-01
JP2012524804A (ja)	2012-10-18
CN102459240A (zh)	2012-05-16
HRP20140295T1 (hr)	2014-04-25
KR20120034615A (ko)	2012-04-12
US20110015171A1 (en)	2011-01-20
AU2010238732B2 (en)	2015-06-11
RU2011147233A (ru)	2013-05-27
JP5649644B2 (ja)	2015-01-07
TWI465446B (zh)	2014-12-21
US8962607B2 (en)	2015-02-24
US20100324011A1 (en)	2010-12-23
US8367653B2 (en)	2013-02-05
US8722658B2 (en)	2014-05-13
WO2010124116A1 (en)	2010-10-28
IL215781A0 (en)	2012-01-31
CA2759621C (en)	2017-09-26
US8362000B2 (en)	2013-01-29
CA2759501A1 (en)	2010-10-28
EP2421824A1 (en)	2012-02-29
RU2011147206A (ru)	2013-05-27
PT2421825E (pt)	2014-03-13
IL215773A0 (en)	2012-01-31
AR076376A1 (es)	2011-06-08
US20130123233A1 (en)	2013-05-16
BRPI1013545A2 (pt)	2019-09-24
BRPI1013538A2 (pt)	2019-09-24
RU2569298C2 (ru)	2015-11-20
WO2010124108A1 (en)	2010-10-28
AU2010239204A1 (en)	2011-11-10
BRPI1014284A2 (pt)	2017-10-10
CA2759697A1 (en)	2010-10-28
RU2011147236A (ru)	2013-05-27
CN102459230A (zh)	2012-05-16
EP2421860A1 (en)	2012-02-29
CA2759614A1 (en)	2010-10-28
CA2759614C (en)	2017-09-19
RS53235B (en)	2014-08-29
CA2759621A1 (en)	2010-10-28
US20130102585A1 (en)	2013-04-25
WO2010124112A1 (en)	2010-10-28
EP2421856A1 (en)	2012-02-29
TWI483940B (zh)	2015-05-11
AU2010238732A1 (en)	2011-11-10
CN102459166A (zh)	2012-05-16
SMT201400034B (it)	2014-05-07
JP2012524802A (ja)	2012-10-18
US20100331300A1 (en)	2010-12-30
EP2421847A1 (en)	2012-02-29
JP2012524801A (ja)	2012-10-18
EP2421825A1 (en)	2012-02-29
US8697683B2 (en)	2014-04-15
KR20110137834A (ko)	2011-12-23
TW201103918A (en)	2011-02-01
AR076377A1 (es)	2011-06-08
TW201116280A (en)	2011-05-16
US8450303B2 (en)	2013-05-28
US8399454B2 (en)	2013-03-19
US8604017B2 (en)	2013-12-10
DK2421825T3 (da)	2014-02-03
US8697684B2 (en)	2014-04-15
EP2421848A1 (en)	2012-02-29
RU2011147181A (ru)	2013-05-27
EP2421825B1 (en)	2014-01-01
RU2011147207A (ru)	2013-05-27
RU2011147230A (ru)	2013-05-27
US8362001B2 (en)	2013-01-29
US20100324014A1 (en)	2010-12-23
KR20120034616A (ko)	2012-04-12
CA2759713A1 (en)	2010-10-28
CA2759547A1 (en)	2010-10-28
CA2759505A1 (en)	2010-10-28
CN102459255A (zh)	2012-05-16
KR20120034617A (ko)	2012-04-12
IL215775A0 (en)	2012-01-31
US8691805B2 (en)	2014-04-08
IL215787A0 (en)	2012-01-31
AR076379A1 (es)	2011-06-08
IL215773A (en)	2015-05-31
US20130237517A1 (en)	2013-09-12
CN102459228A (zh)	2012-05-16
US20130217669A1 (en)	2013-08-22
JP2012524805A (ja)	2012-10-18
AU2010239184A1 (en)	2011-11-10
US20130244997A1 (en)	2013-09-19
BRPI1014885A8 (pt)	2018-04-10
TW201103930A (en)	2011-02-01
AU2010239188B2 (en)	2016-03-31
AU2010238740A1 (en)	2011-11-10
AU2010238743A1 (en)	2011-11-10
IL215780A (en)	2015-05-31
JP2012524806A (ja)	2012-10-18
AU2010238736A1 (en)	2011-11-10
CN102459166B (zh)	2015-03-25
CN102459167A (zh)	2012-05-16
AR076380A1 (es)	2011-06-08
US20140243305A1 (en)	2014-08-28
HK1170221A1 (en)	2013-02-22
WO2010124102A1 (en)	2010-10-28
CN102459167B (zh)	2015-04-01
US8426401B2 (en)	2013-04-23
US8445477B2 (en)	2013-05-21
IL215785A0 (en)	2012-01-31
WO2010124119A1 (en)	2010-10-28
JP2012524800A (ja)	2012-10-18
IL215780A0 (en)	2012-01-31
EP2421823B1 (en)	2015-01-14
RU2011147200A (ru)	2013-05-27
US8741887B2 (en)	2014-06-03
AR076382A1 (es)	2011-06-08
TW201105665A (en)	2011-02-16
KR101705697B1 (ko)	2017-02-10
ES2538326T3 (es)	2015-06-19
IL215786A0 (en)	2012-01-31
AU2010239188A1 (en)	2011-11-10
US20130137674A1 (en)	2013-05-30
US8455476B2 (en)	2013-06-04
AR076378A1 (es)	2011-06-08
US20130123232A1 (en)	2013-05-16
WO2010124082A1 (en)	2010-10-28
US20110015170A1 (en)	2011-01-20
JP2012524807A (ja)	2012-10-18
IL215798A0 (en)	2012-01-31
KR20110137831A (ko)	2011-12-23
KR101705049B1 (ko)	2017-02-09
PL2421825T3 (pl)	2014-06-30
BRPI1015238A2 (pt)	2019-09-24
AR076381A1 (es)	2011-06-08
CN102803210A (zh)	2012-11-28
KR20120035146A (ko)	2012-04-13
KR20120034622A (ko)	2012-04-12
TW201103932A (en)	2011-02-01
US20100324012A1 (en)	2010-12-23
BRPI1013540A2 (pt)	2020-11-17
EP2421823A1 (en)	2012-02-29
WO2010124114A1 (en)	2010-10-28
US8623858B2 (en)	2014-01-07
EP2421851A1 (en)	2012-02-29
HK1170228A1 (en)	2013-02-22
KR20120034623A (ko)	2012-04-12
AR076374A1 (es)	2011-06-08
JP2012524803A (ja)	2012-10-18
ES2455744T3 (es)	2014-04-16
BRPI1014281A2 (pt)	2019-09-24
US20100324013A1 (en)	2010-12-23
AU2010238738A1 (en)	2011-11-10

Publication	Publication Date	Title
BRPI1014885A2 (pt)	2016-04-19	"azetidinil diamidas como inibidores de monoacilglicerol lipase."
BR112013009858A2 (pt)	2016-07-26	diamidas de piperidin-4-il-azetidina como inibidores de monoacilglicerol lipase
BR112012012872A2 (pt)	2017-10-10	"pirrolindinas de espiroindolinona"
BRPI1008890A2 (pt)	2015-08-25	Formulações de caldos de fermentação
FR2957244B1 (fr)	2012-04-13	Implant d'arthrodese
BR112012003787A2 (pt)	2017-07-04	variantes de glicoamilase
IL225815A0 (en)	2013-06-27	Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
BRPI0924425A2 (pt)	2015-08-11	"combinações de substâncias ativas sinergéticas".
BRPI1016228A2 (pt)	2016-04-26	formulações de eletrólito compatibilizadas
BR112012000914A2 (pt)	2017-08-08	diferenciação de cádula-tronco mesenquimal
BRPI1013001A2 (pt)	2015-09-15	"bioprocessamento"
FR2944062B1 (fr)	2011-06-03	Injecteur d'ergols
BRPI1014888A2 (pt)	2019-09-24	piperazinil azetidinil amidas heteroaromáticas e aromáticas como inibidores de monoacilglicerol lipase
BRPI1006058A2 (pt)	2015-09-01	"fermentação de carboidrato"
BRPI1014874A2 (pt)	2016-04-12	piperazinil azetidinil amidas heteroaromáticas e aromáticas como inibidores de monoacilglicerol lipase
BR112012002596A2 (pt)	2015-09-15	formulações de polipeptídeo concentradas com viscodidade reduzida
BRPI1015272A2 (pt)	2015-08-25	Fermentação
BRPI1014457A2 (pt)	2015-08-25	"n-(4-perfluoro-alquil-fenil)-4-triazolil-benzamidas como inseticidas"
BRPI0917522A2 (pt)	2015-07-28	Protetores de cultura
BRPI1013017A2 (pt)	2016-03-29	"17beta-alquil-17alfa-óxi-estratrienos"
UY33138A (es)	2011-07-29	Formulaciones liquidas
ITVA20070023A1 (it)	2008-09-02	Esteri idrossammici come fotoiniziatori
TH101265B (th)	2010-04-30	ส่วนปลายของกระป๋อง
TH105198B (th)	2010-11-27	ส่วนปลายของกระป๋อง
BRPI1007935A2 (pt)	2015-09-01	"combinações de compostos ativos"

Legal Events

Date	Code	Title	Description
2016-09-20	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 6A ANUIDADE.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.